(-)-Lobeline

洛贝林

Report date: 2022/09/08 13:39:52
NME

Base Information

Drug Name(-)-Lobeline
Drug Alias NamelobelinalobelinumC-07475
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMu opioid receptor antagonistsDopamine receptors modulators
TargetsDopamine receptorsMu opioid receptor
Therapy Area/IndicationsAttention Deficit Disorder with HyperactivityAmphetamine-Related DisordersSubstance-Related Disorders +[5] 
Global Approved IndicationsPoisoningAsphyxia Neonatorum
Approved Indications in ChinaPoisoningAsphyxia Neonatorum
Original Approved Country/TerritoryMainland China
Original Approved Date1981/01/01
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesActelion Pharmaceuticals Ltd
China Registration ClassN/A

Develop Information

Active CompaniesChengdu First Pharmaceutical Co Ltd
Inactive CompaniesNational Institute On Drug AbuseYaupon Therapeutics Inc
Active IndicationsPoisoningAsphyxia Neonatorum
Inactive IndicationsAttention Deficit Disorder with HyperactivityAmphetamine-Related DisordersSubstance-Related Disorders

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG